Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-Label, Dose Escalation Study of Daily Dosing With BB-10901

NCT00346385 is registered in ClinicalTrials.gov with ImmunoGen, Inc. as lead sponsor.

NCT NCT00346385
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00346385 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-Label, Dose Escalation Study of Daily Dosing With BB-10901
Lead sponsor
ImmunoGen, Inc.
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2002
Completion date
October 31, 2011
Enrollment
97 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

merkel cell carcinoma, ovarian cancer, sclc